Open company graph database — free web & API
Login

Lucasana Biotech Inc.

ルクサナバイオテク株式会社Luxna BiotechAlias
Ticker
—
Listed market
—
Country
Japan
Employees (non-consolidated)
—
Related companies
2
§01

Basic information

BASIC
Head office
2-8 Yamadaoka, Suita City, Osaka Prefecture 565-0871, Techno Alliance C Building, 9F, C907Sources
Chief executive
Shuichi SatoSources
Capital
90,000,000 Sources
Employees (non-consolidated)
Employees (consolidated)
Start date
2017-12-18Sources
End date
§02

Websites

1 DOMAINS
§03

Business

4
Collaborative drug discovery with pharmaceutical companiesSourcesXNAs technology licensing businessSourcesIn-house drug discovery businessSourcesXNAs monomer supply businessSources
§04

Related companies

2 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
KH Neochem Corporation
Inabata & Co., Ltd.
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§07

News

22 ARTICLES

BioJapan 2026 and JHVS PresentationSources

LUXANA Biotech Co., Ltd. will exhibit at BioJapan 2026 and give a presentation at the JHVS SHOWCASE of the Japan Healthcare Venture Summit 2026. President Hideaki Sato will participate as the representative, introducing the company's technologies and future plans.

LUXANA Biotech, Announcement of Exhibiting and Presenting at BioJapan 2026Sources

LUXANA Biotech Inc. will exhibit at BioJapan 2026, and CEO and President Hideaki Sato will pitch at the JHVS SHOWCASE of the Japan Healthcare Venture Summit 2026. The company will introduce its business overview, technological strengths, and future plans, aiming to pursue new business collaborations and joint research opportunities.

Luxna Biotech and Servier enter collaborationSources

Luxna Biotech Co., Ltd. has entered into a research collaboration agreement with Servier that includes an option to license its proprietary XNA technology for neurological diseases. Following successful completion of the first milestone in the drug discovery program, Luxna will receive a milestone payment and proceed to the next stage of research.

Luxna Biotech Signs Joint Research Agreement with ServierSources

Luxna Biotech Co., Ltd. signed a joint research agreement with French pharmaceutical company Servier, including a license option for exclusive rights to Luxna XNA technology in neurological diseases. The agreement follows achievement of a milestone in the first stage of joint drug discovery research launched in April 2024. Luxna will receive a milestone payment and proceed to the second stage.

Antisense therapy for glaucoma in a monkey modelSources

Takaaki Kawanobe, Ph.D., deputy biology group lead at Luxna Biotech Co., Ltd., will give an oral presentation on the neuroprotective effects of antisense oligonucleotide therapy in a cynomolgus monkey model of ocular hypertension-induced glaucoma at the 37th meeting of the Japan Glaucoma Society. The presentation is scheduled for October 3, 2026, at Shizuoka Convention & Arts Center GRANSHIP.

Presentation at the 37th Annual Meeting of the Japanese Glaucoma SocietySources

Shunsuke Kawanobe, deputy group leader of the company’s Biology Group, will give an oral presentation in the basic research category at the 37th Annual Meeting of the Japanese Glaucoma Society on Saturday, October 3, 2026. He will present neuroprotective effects of antisense oligonucleotide therapy in cynomolgus monkeys with ocular hypertension glaucoma. The meeting will be held at Shizuoka Convention & Arts Center Granship. Visitors are welcome.

Hideaki Sato to speak at RNA Leaders APAC 2026Sources

Hideaki Sato, president and CEO of Luxna Biotech, will speak at RNA Leaders APAC 2026 in Singapore on September 1 at 2:30 p.m. local time. His presentation, “Driving Innovation in Antisense Therapeutics for Intractable Diseases Using Artificial Nucleic Acid Technologies and Ophthalmological Applications,” will introduce the company’s proprietary LuxiAP™ platform and cover its research and development of next-generation antisense oligonucleotide therapeutics for intractable diseases.

Mr. Sato to Speak at RNA Leaders APAC 2026Sources

Mr. Sato, representative of Luxna Biotech Co., Ltd., will speak at RNA Leaders APAC 2026, to be held at Marina Bay Sands in Singapore on September 1 and 2, 2026. He will discuss research and development of next-generation antisense oligonucleotide therapeutics for intractable diseases, centered on the company’s proprietary LuxiAP™ nucleic acid drug platform, applications in neurological and ophthalmic fields, and the latest results from its glaucoma treatment program.

GuNA research article featured on Organic & Biomolecular Chemistry coverSources

A research article related to GuNA, co-authored by Luxna Biotech researchers, was featured on the cover of Organic & Biomolecular Chemistry. It describes an improved guanidine protecting group that enables efficient synthesis of GuNA[t-Bu]-modified antisense oligonucleotides and may advance modified nucleic acid technologies.

GuNA Paper Featured on Cover of Organic & Biomolecular ChemistrySources

A paper on GuNA co-authored by the company’s researchers was selected for the cover of Organic & Biomolecular Chemistry, published by the Royal Society of Chemistry. It reports an improved guanidine protecting group that enables efficient synthesis of GuNA[t-Bu]-modified antisense oligonucleotides and is expected to advance modified nucleic acid technologies.

§08

Public records

GOV
National Tax Agency basic information7120901039358
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
ルクサナバイオテク株式会社
Trade name (kana)
ルクサナバイオテク
Name in English
Luxna Biotech Co., Ltd.
Corporation type
301
Address
〒565-0871 大阪府吹田市山田丘2番8号
Postal code
5650871
Prefecture code
27
City code
205
Address outside Japan
Prefecture in English
Osaka
City in English
2-8 Yamadaoka, Suita shi
Address outside Japan in English
Corporate number assignment date
2017-12-21
Update date
2021-04-09
Change date
2020-01-06
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
1
Trade name image ID
Address image ID
Sequence number
4345678
METI gBizINFO7120901039358
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
7120901039358
Trade name
ルクサナバイオテク株式会社
Trade name (kana)
ルクサナバイオテク
Trade name (alphabet)
Luxna Biotech Co., Ltd.
Registry closure date
Reason for registry closure
Registered address
大阪府吹田市山田丘2番8号
Postal code
5650871
Prefecture
大阪府
Prefecture code
27
City or district
吹田市
City code
205
Street address
山田丘2番8号
Organisation type
301
Processing type
12
Correction type
1
Status
Representative
Capital
Employees
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2021-04-09
Key information
7120901039358
§09

Sources & updates

SOURCES
↑